Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Kioa Lente Wijnsma, Rob ter Heine, Dirk Jan A.R. Moes, Saskia Langemeijer, Saskia E.M. Schols, Elena B. Volokhina, Lambertus P. van den Heuvel, Jack F.M. Wetzels, Nicole C.A.J. van de Kar, Roger J. Brüggemann

Research output: Contribution to journalReview articlepeer-review

80 Citations (Scopus)

Abstract

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.

Original languageEnglish
Pages (from-to)859-874
Number of pages16
JournalClinical Pharmacokinetics
Volume58
Issue number7
DOIs
Publication statusPublished - 1 Jul 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab'. Together they form a unique fingerprint.

Cite this